Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Effekte bei Zielorganschädigung (16 Abbildungen)
Übersicht


Abb. 0: FÜR ÖSTERREICH: Weitere Informationen: Merck Gesellschaft mbH, Zimbagasse 5, 1147 Wien, Tel.: 01/576 00-0 Abb. 1: Effekte bei Zielorganschädigung Aktuelles Bild - Abb. 2: Telmisartan - Renoprotektiver Effekt Abb. 3: Telmisartan - Renoprotektiver Effekt Abb. 4: Telmisartan - Renoprotektiver Effekt Abb. 5: Telmisartan - Renoprotektiver Effekt Abb. 6: Telmisartan - Renoprotektiver Effekt Zum letzten Bild
Abbildung 2: Telmisartan - Renoprotektiver Effekt
The Telmisartan versus Ramipril in renal ENdothelial DYsfunction (TRENDY) study showed that telmisartan improves endothelial function in the kidneys of patients with type 2 diabetes, good renal function and low or absent microalbuminuria [1]. The 96 patients had mild-to-moderate hypertension (seated SBP/DBP 140–180/90–110 mmHg), normo- or microalbuminuria and GFR > 80 mL/min/1.73 m2. They received telmisartan 40 mg or ramipril 5 mg for 3 weeks, followed by telmisartan 80 mg or ramipril 10 mg for 6 weeks, with add-on therapy (HCTZ, metoprolol or atenolol) to ensure blood pressure control. Endothelial function was assessed by measuring renal plasma flow in response to the infusion of N(G)-monomethyl-L-arginine acetate (L-NMMA). The percentage change from baseline in endothelial function is shown in this slide. 1. Schmeider RE, et al. Effects of telmisartan versus ramipril on renal endothelial function in Type-2 diabetes. Presented at the XVIth Scientific Meeting of the Interamerican Society of Hypertension. Cancún, México, April 17–21, 2005.
 
Telmisartan - Renoprotektiver Effekt
Vorheriges Bild Nächstes Bild   


Abbildung 2: Telmisartan - Renoprotektiver Effekt
The Telmisartan versus Ramipril in renal ENdothelial DYsfunction (TRENDY) study showed that telmisartan improves endothelial function in the kidneys of patients with type 2 diabetes, good renal function and low or absent microalbuminuria [1]. The 96 patients had mild-to-moderate hypertension (seated SBP/DBP 140–180/90–110 mmHg), normo- or microalbuminuria and GFR > 80 mL/min/1.73 m2. They received telmisartan 40 mg or ramipril 5 mg for 3 weeks, followed by telmisartan 80 mg or ramipril 10 mg for 6 weeks, with add-on therapy (HCTZ, metoprolol or atenolol) to ensure blood pressure control. Endothelial function was assessed by measuring renal plasma flow in response to the infusion of N(G)-monomethyl-L-arginine acetate (L-NMMA). The percentage change from baseline in endothelial function is shown in this slide. 1. Schmeider RE, et al. Effects of telmisartan versus ramipril on renal endothelial function in Type-2 diabetes. Presented at the XVIth Scientific Meeting of the Interamerican Society of Hypertension. Cancún, México, April 17–21, 2005.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung